IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.176
NA - Nord America 3.114
AS - Asia 1.675
SA - Sud America 101
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 8.093
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.101
CN - Cina 635
SG - Singapore 540
UA - Ucraina 527
IE - Irlanda 507
IT - Italia 483
GB - Regno Unito 375
SE - Svezia 352
TR - Turchia 342
FR - Francia 326
DE - Germania 205
FI - Finlandia 125
PL - Polonia 100
BR - Brasile 99
RU - Federazione Russa 95
IN - India 78
CZ - Repubblica Ceca 27
HK - Hong Kong 24
BE - Belgio 23
AT - Austria 11
VN - Vietnam 10
JP - Giappone 9
IR - Iran 7
MX - Messico 7
NL - Olanda 7
ZA - Sudafrica 7
AE - Emirati Arabi Uniti 6
EU - Europa 5
BD - Bangladesh 4
BY - Bielorussia 4
CA - Canada 4
AU - Australia 3
EG - Egitto 3
GR - Grecia 3
IL - Israele 3
MA - Marocco 3
AZ - Azerbaigian 2
PH - Filippine 2
PK - Pakistan 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
ES - Italia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
ID - Indonesia 1
IQ - Iraq 1
KZ - Kazakistan 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 8.093
Salva come PNG Salva come JPEG
Città #
Chandler 662
Jacksonville 583
Dublin 498
Singapore 349
Southend 312
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Ashburn 112
Beijing 106
Wilmington 101
Kraków 98
Cambridge 95
Chieti 83
Altamura 79
The Dalles 70
Ann Arbor 67
Nanchang 64
Boardman 53
Santa Clara 51
Shenyang 42
Woodbridge 38
Munich 34
Hebei 29
Changsha 28
Grevenbroich 27
Los Angeles 26
Helsinki 24
Hong Kong 24
Pescara 24
Jiaxing 23
Brno 22
Tianjin 22
Camerino 21
Kocaeli 21
Washington 21
Brussels 20
Kunming 20
New York 18
Orange 17
Seattle 17
Shanghai 17
Hangzhou 16
Spoltore 16
Norwalk 15
Düsseldorf 12
Nuremberg 12
Hefei 11
Jinan 11
Leawood 11
Rome 11
Lanzhou 10
São Paulo 10
Dong Ket 9
Guangzhou 9
Augusta 8
Houston 8
Lappeenranta 8
Montesilvano 8
Romola 8
Menlo Park 7
Silvi 7
Cape Town 6
Fuzhou 6
L’Aquila 6
Ningbo 6
San Mateo 6
Simi Valley 6
Vienna 6
Auburn Hills 5
Dubai 5
Moscow 5
Olomouc 5
Padova 5
Perm 5
Taizhou 5
Tavagnacco 5
Changchun 4
Mogilev 4
Mumbai 4
Tappahannock 4
Zhengzhou 4
Ardabil 3
Bari 3
Brasília 3
Frankfurt am Main 3
Glasgow 3
Mexico City 3
Sagamino 3
San Giovanni Teatino 3
Tagara 3
Toronto 3
Walnut 3
Amsterdam 2
Ankara 2
Antalya 2
Anzano Del Parco 2
Ashford 2
Avezzano 2
Totale 4.999
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 194
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 129
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 118
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 112
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 112
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 108
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 106
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 105
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 104
Antithrombotic Agents and Cancer 99
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 96
Oxidative stress and platelet activation in essential hyperytension 95
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 94
null 93
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 93
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 92
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 92
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 92
New insights into COX-2 biology and inhibition. 90
Platelet activation in patients with colorectal cancer. 90
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 90
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 89
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 89
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 89
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 87
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 85
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 85
Pharmacodynamic of cyclooxygenase inhibitors in humans. 85
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 84
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 84
Mechanistic and pharmacological issues of aspirin as an anticancer agent 84
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 84
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 83
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 81
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 81
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 80
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 79
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 78
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 77
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 77
Clinical pharmacology of selective COX-2 inhibitors. 77
Gut microbiota, host gene expression, and aging. 77
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 76
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 75
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 75
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 75
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 75
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 74
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 74
P2Y12 Receptors in Tumorigenesis and Metastasis 74
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 73
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 73
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 73
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 73
NSAIDs and cardiovascular disease. 73
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 72
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 72
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 72
Risk management profile of etoricoxib: An example of personalized medicine 72
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 71
Clinical pharmacology of novel selective COX-2 inhibitors. 71
Determinants of platelet activation in human essential hypertension. 71
Human pharmacology of naproxen sodium. 71
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 70
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 70
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 70
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 69
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 66
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 66
Clinical pharmacology of etoricoxib. 65
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 65
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 65
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 65
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 64
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 63
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 63
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 63
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 63
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 62
null 62
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 61
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 61
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 61
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 61
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 60
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 60
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 60
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 59
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 59
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. 59
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 59
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 58
Mode of action of aspirin as a chemopreventive agent. 57
null 57
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 56
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 56
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 55
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 55
Isoprostanes and other markers of peroxidation in atherosclerosis. 53
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 53
Totale 7.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020131 0 0 0 0 0 0 0 0 0 0 122 9
2020/2021752 110 2 107 8 69 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.294 123 272 198 43 52 98 67 143 156 103 39 0
Totale 8.544